Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Gains from Investment Securities (2018 - 2026)

Champions Oncology has reported Gains from Investment Securities over the past 8 years, most recently at -$89000.0 for Q1 2026.

  • For Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$89000.0; the TTM value through Jan 2026 reached -$402000.0, down 1575.0%, while the annual FY2025 figure was -$293000.0, 300.68% down from the prior year.
  • Gains from Investment Securities for Q1 2026 was -$89000.0 at Champions Oncology, down from -$20000.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $96000.0 in Q1 2024 and troughed at -$293000.0 in Q2 2025.
  • A 4-year average of -$32000.0 and a median of -$22000.0 in 2024 define the central range for Gains from Investment Securities.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 150.0% in 2024 and later tumbled 1120.83% in 2025.
  • Year by year, Gains from Investment Securities stood at $74000.0 in 2023, then tumbled by 150.0% to -$37000.0 in 2024, then soared by 45.95% to -$20000.0 in 2025, then tumbled by 345.0% to -$89000.0 in 2026.
  • Business Quant data shows Gains from Investment Securities for CSBR at -$89000.0 in Q1 2026, -$20000.0 in Q3 2025, and -$293000.0 in Q2 2025.